PP
RUBY

Paloma Partners’s Rubius Therapeutics, Inc RUBY Stock Holding History

Paloma Partners’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,917
Closed -$105K – 2385
2020
Q3 		$105K Buy
+20,917
New +$111K ﹤0.01% 1900

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paloma Partners's RUBY Position: Q4 2020 in Review

Paloma Partners sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2020, closing a stake of 20,917 shares — an estimated $105K sold.

Paloma Partners first reported a position in RUBY in Q3 2020 and held it in 1 quarter. The position peaked at $105K in Q3 2020. 87 funds tracked by Wall St. Rank hold RUBY as of Q4 2020.

  • Paloma Partners reported no remaining Rubius Therapeutics, Inc position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 20,917 Rubius Therapeutics, Inc shares in Q4 2020, an estimated $105K.
  • Paloma Partners first reported a position in Rubius Therapeutics, Inc in Q3 2020 and held it in 1 quarter.
  • Paloma Partners's Rubius Therapeutics, Inc position peaked at $105K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.